Orphanet: Simple search
x

Search for a diagnostic test

* (*) mandatory field

28 Result(s)

Filter by

Speciality(ies)/objective(s)

Technique(s)

Purpose(s)

Quality management

Country(ies)

Reset
Sort by

Caption : Accreditation =Accreditation
;

FRANCE

ILE-DE-FRANCE
PARIS

Accreditation
Pharmacogenetics analysis of CYP2C19 gene
CHU Paris IdF Ouest - HEGP Hôpital Européen Georges Pompidou
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

FRANCE

ILE-DE-FRANCE
LE KREMLIN-BICÊTRE

Accreditation
Pharmacogenetics analysis of CYP2C19 gene
CHU Paris-Sud - Hôpital de Bicêtre
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

FRANCE

HAUTS-DE-FRANCE
LILLE

Accreditation
Pharmacogenetics analysis of CYP2C19 gene
CHU de Lille - Centre de Biologie Pathologie Génétique
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region
Technique(s) : Sanger sequencing

GERMANY

Hessen
FRANKFURT AM MAIN

Accreditation
Pharmacogenetic analysis of CYP2C19 gene
bio.logis Zentrum für Humangenetik
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : Sanger sequencing

SPAIN

Castilla - León
SALAMANCA

Accreditation
Pharmacogenetics analysis of CYP2C19 gene
Hospital Clínico Universitario de Salamanca
Purpose(s) : Pharmacogenetics, Risk assessment
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

GERMANY

Bayern
MARTINSRIED

Accreditation
Pharmacogenetic analysis of CYP2C19 gene
Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ)
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

FRANCE

NORMANDIE
ROUEN

Accreditation
Pharmacogenetics analysis of CYP2C19 gene
CHU de Rouen
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

GERMANY

Bayern
MÜNCHEN

Accreditation
Pharmacogenetic analysis of CYP2C19 gene
Pränatalmedizin München
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region, Deletion / Duplication analysis
Technique(s) : Sanger sequencing, MLPA based techniques

GERMANY

Hamburg
HAMBURG

Accreditation
Pharmacogenetic analysis of CYP2C19 gene
Labor Lademannbogen
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis, Sequence analysis: entire coding region, Deletion / Duplication analysis
Technique(s) : Sanger sequencing, MLPA based techniques

FRANCE

PROVENCE-ALPES-COTE D'AZUR
MARSEILLE

Accreditation
Pharmacogenetics analysis of CYP2C19 gene
CHU de Marseille - Hôpital de la Conception
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis, Deletion / Duplication analysis
Technique(s) : NGS sequencing (except WES), Sanger sequencing, PCR based techniques

FRANCE

ILE-DE-FRANCE
LE KREMLIN-BICÊTRE

Accreditation
Pharmacogenetics analysis of CYP2C19*17 gene
CHU Paris-Sud - Hôpital de Bicêtre
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

FRANCE

OCCITANIE
TOULOUSE

Accreditation
Pharmacogenetics analysis of CYP2C19 gene
Institut Fédératif de Biologie
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

SWITZERLAND

Suisse Romande
GENÈVE

Accreditation
Pharmacogenetic analysis of ADME (absorption,distribution,metabolism and excretion) (Panel)
Hôpitaux Universitaires de Genève HUG
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region
Technique(s) : NGS sequencing (except WES)

FINLAND

Finland
KUOPIO

Accreditation
Pharmacogenetics analysis of responses to clopidogrel (CYP2C19 gene)
University of Eastern Finland
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : Sanger sequencing, PCR based techniques

NETHERLANDS

Zuid-Holland
ROTTERDAM

Accreditation
Pharmacogenetic analysis of CYP2C19 gene variants (variant *1, *2, *3, *4, *5, *6, *7, *8, *9, *10 and *17)
Erasmus MC - Erasmus Medisch Centrum
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

AUSTRIA

WIEN
WIEN

Accreditation
Pharmacogenetics analysis of the CYP2C19 gene
Medizinische Universität Wien
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

FRANCE

AUVERGNE-RHONE-ALPES
PIERRE-BENITE

Pharmacogenetics analysis of CYP2C19 gene
CHU de Lyon HCL - GH Sud
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis, Deletion / Duplication analysis
Technique(s) : PCR based techniques, MLPA based techniques

SPAIN

Comunidad Valenciana
ELCHE

Diagnosis of rare epilepsy (panel)
Bioarray
Purpose(s) : Post-natal diagnosis
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region
Technique(s) : NGS sequencing (except WES)

FRANCE

OCCITANIE
MONTPELLIER

Pharmacogenetics analysis of hematology (Panel)
CHU de Montpellier - Hôpital Saint-Eloi
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Mutation scanning/screening and sequence analysis of selected exons
Technique(s) : NGS sequencing (except WES)

SPAIN

Madrid
SAN SEBASTIÁN DE LOS REYES

Diagnosis of major susceptibility to antidepressant or antipsychotic toxicity or dose selection, Voriconazole toxicity and resistance to Clopidogrel (CYP2C19 gene)
LabGenetics - Laboratorio de Genética Clínica, S.L.
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis, Mutation scanning/screening and sequence analysis of selected exons, Sequence analysis: entire coding region
Technique(s) : Sanger sequencing

SWITZERLAND

Suisse Romande
LAUSANNE

Pharmacogenetics analysis of CYP2C19 gene (*1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *17)
Gene Predictis SA
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : Sanger sequencing, PCR based techniques

FRANCE

AUVERGNE-RHONE-ALPES
PIERRE-BENITE

Pharmacogenetics analysis of CYP2C19 gene
CHU de Lyon HCL - GH Sud
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

ISRAEL

ISRAEL
TEL AVIV

Pharmacogenetics testing for clopidogrel metabolism (CYP2C19 gene)
Pronto Diagnostics Ltd.
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

FRANCE

ILE-DE-FRANCE
PARIS

Pharmacogenetics analysis of CYP2C19 gene
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Lariboisière
Purpose(s) : Post-natal diagnosis, Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques

CZECH REPUBLIC

South Bohemia
CESKE BUDEJOVICE

Pharmacogenetics analysis of the CYP2C19 gene
Hospital Ceské Budejovice
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

PORTUGAL

SUL
LISBOA

Pharmacogenetics analysis of CYP2C19 gene
Faculdade de Medicina da Universidade de Lisboa
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis

GERMANY

Berlin
BERLIN

Diagnosis of cancer (NGS screening panel, 402 genes)
ATG GenMed GmbH
Purpose(s) : Post-natal diagnosis, Somatic genetics
Specialty(ies) : Molecular genetics
Objective(s) : Sequence analysis: entire coding region
Technique(s) : NGS sequencing (except WES)

POLAND

Kraków
KRAKOW

Cyp2D6 and Cyp2C19 in pharmacogenomic diagnostics
Uniwersytet Jagiellonski
Purpose(s) : Pharmacogenetics
Specialty(ies) : Molecular genetics
Objective(s) : Targeted mutation analysis
Technique(s) : PCR based techniques